RNA-based CRISPR-Mediated Loss-of-Function Mutagenesis in Human Pluripotent Stem Cells

J Mol Biol. 2020 Jun 12;432(13):3956-3964. doi: 10.1016/j.jmb.2020.04.017. Epub 2020 Apr 25.

Abstract

Current approaches for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated-9 (Cas9)-mediated genome editing in human pluripotent stem (PS) cells mainly employ plasmids or ribonucleoprotein complexes. Here, we devise an improved transfection protocol of in vitro transcribed Cas9 mRNA and crRNA:tracrRNA duplex that can effectively generate indels in four genetic loci (two active and two inactive) and demonstrate utility in four human PS cell lines (one embryonic and three induced PS cell lines). Our improved protocol incorporating a Cas9-linked selection marker and a staggered transfection strategy promotes targeting efficiency up to 85% and biallelic targeting efficiency up to 76.5% of total mutant clones. The superior targeting efficiency and the non-integrative nature of our approach underscore broader applications in high-throughput arrayed CRISPR screening and in generating custom-made or off-the-shelf cell products for human therapy.

Keywords: Cas9 messenger RNA; clustered regularly interspaced short palindromic repeats; crRNA:tracrRNA duplex; lipofection; transfection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CRISPR-Cas Systems / genetics*
  • Gene Editing
  • Humans
  • Loss of Function Mutation / genetics
  • Mutagenesis / genetics*
  • Pluripotent Stem Cells / cytology*
  • RNA / genetics*
  • RNA, Guide, CRISPR-Cas Systems
  • Transfection

Substances

  • RNA, Guide, CRISPR-Cas Systems
  • RNA